-+ 0.00%
-+ 0.00%
-+ 0.00%

OMass Therapeutics raises $310 million in Series C round co-led by Forbion

PUBT·10/15/2026 07:12:01
OMass Therapeutics raises $310 million in Series C round co-led by Forbion
  • OMass Therapeutics raised $310 million (£230 million) in an oversubscribed Series C financing co-led by Bain Capital Life Sciences, Forbion and Novo Holdings.
  • The biotechnology company develops small-molecule therapeutics for endocrine and immunologic diseases.
  • Proceeds will advance OMS1620 through Phase 2 development for congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome.
  • Funding will also support initial clinical data for an SLC15A4 inhibitor targeting lupus and other immune-related diseases.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Forbion Capital Partners Management Services BV published the original content used to generate this news brief on October 15, 2026, and is solely responsible for the information contained therein.